The Growing Demand For Effective Treatments Is Fueling The Market Growth Due To The Rising Prevalence Of Chronic And Complex Conditions Is Supporting Development Across The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market During 2026–2030?

The primary progressive multiple sclerosis (ppms) treatment market has experienced rapid expansion in recent years. It is projected to grow from $1.16 billion in 2025 to $1.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. Historically, this growth was influenced by factors such as the restricted availability of treatment options for ppms, the dependence on corticosteroids for managing symptoms, insufficient patient awareness of ppms, an underdeveloped hospital pharmacy infrastructure, and the slow integration of immunosuppressants.

The primary progressive multiple sclerosis (ppms) treatment market is projected to experience substantial expansion over the coming years. It is forecast to reach $2.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This anticipated growth during the forecast period is largely due to factors such as the introduction of targeted monoclonal antibodies, intensified research and development efforts in neurodegenerative disorders, the broadening reach of hospital and online pharmacy networks, an increase in regulatory approvals for new therapeutic options, and enhanced patient awareness and early diagnosis initiatives. Key trends expected during this period involve the increasing uptake of monoclonal antibodies for ppms, a heightened emphasis on symptom management and improving quality of life, a growing preference for intravenous drug administration, the expansion of hospital and specialty pharmacy channels, and the ongoing development of innovative therapeutics and combination treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

What Major Growth Factors Are Impacting The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The increasing need for successful therapies is projected to boost the primary progressive multiple sclerosis (PPMS) treatment market going forward. Effective treatments are medical interventions that lessen symptoms, improve patient results, or cure a disease or condition. This rising demand is primarily fueled by the growing occurrence of chronic and complex health conditions, which require sustained management and advanced therapeutic interventions to enhance patient outcomes and quality of life. Such treatments are vital for slowing the progression of primary progressive multiple sclerosis (PPMS) by targeting inflammation and preserving neurological function, thus improving long-term quality of life, reducing disability accumulation, and empowering patients to manage daily activities with greater independence and stability. For example, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization focused on gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 trials in 2023, representing a 10% increase compared to 2022 and the first quarterly rise since Q3 2022. Consequently, the growing demand for effective treatments is a key driver for the primary progressive multiple sclerosis (PPMS) treatment market.

What Key Segment Areas Are Included In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Assessment?

The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

Which Trends Are Supporting The Evolution Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Leading companies in the primary progressive multiple sclerosis (PPMS) treatment market are concentrating on creating advanced formulations, including monoclonal antibody drugs, to improve therapy for multiple sclerosis. A monoclonal antibody drug supports multiple sclerosis patients by targeting specific immune cells or proteins that trigger inflammation and harm the nervous system, thereby lessening disease activity and slowing the progression of symptoms. As an illustration, in February 2024, Roche Pharma India, a pharmaceutical company based in India, launched Ocrevus (ocrelizumab), a monoclonal antibody drug, for treating multiple sclerosis (MS) within India. Ocrevus stands out as the first and only approved disease-modifying therapy (DMT) in the country for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). This medication operates by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response observed in MS. It is delivered as a twice-yearly intravenous infusion over only two hours, presenting patients with a more convenient and effective treatment choice.

Who Are The Prominent Players Across The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

Access The Complete Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

Which Region Leads The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market By Size?

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company

Multiple Sclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Atherosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Focal Segmental Glomerulosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info